Effect of esketamine adjunct to propofol in male patients undergoing rigid cystoscopic ureteral stent removal

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400088880

Enrollment

Unknown

Registered

2024-08-28

Start date

2024-10-01

Completion date

Unknown

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urolithiasis

Interventions

E2:Esketamine0.25mg/kg+ Propofol

E0:Normal Saline + Propofol

E1:Esketamine0.15mg/kg + Propofol

E3:Esketamine0.35mg/kg+ Propofol

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Male patients, aged 18 to 65 years, BMI 18-28 kg/m2 (2)ASA physical status I–II (3)scheduled for rigid cystoscopic ureteral stent removal

Exclusion criteria

Exclusion criteria: (1) abnormal urinary tract anatomy; (2) unstable heart diseases; (3) hyperthyroidism; (4) central nervous system diseases; (5) neuropsychiatric disorders or drug abuse; (6) allergic to the study drugs; (7) ocular hypertension.

Design outcomes

Primary

Measure	Time frame
Incidence of intraoperative hypoxemia;	—

Secondary

Measure	Time frame
total propofol dosage;Incidence of adverse events;	—

Countries

China

Contacts

Public ContactYu Qingqing

The First People's Hospital Of Hangzhou Lin'an District

mazui_qing@126.com+86 137 7702 6255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026